BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells. Its stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety.
The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice.
Results show its cellular products are safe and effective in the improvement of symptoms related to chronic inflammation, spinal cord injury, stroke, musculoskeletal disorders and other medical conditions.
Multiple studies of umbilical cord blood derived stem cell therapies and adipose-derived stem cell therapies are currently under investigation in clinical trials for a wide-range of medical conditions and show promising results.
The Food and Drug Administration (FDA) has given BHITS approval to proceed with an Investigational New Drug (IND) application allowing for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke.
For more information, please visit www.bhisciences.com.
